Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCHERING-PLOUGH, LaSALLE LABS AGREEMENT FOR GYNECOLOGICAL HORMONE PRODUCTS

Executive Summary

SCHERING-PLOUGH, LaSALLE LABS AGREEMENT FOR GYNECOLOGICAL HORMONE PRODUCTS calls for codevelopment and comarketing in the U.S. and Canada. The first two products to be marketed under the agreement, announced on April 29, will be "a natural oral progesterone and a transdermal estradiol gel, both of which are under review" by FDA, Schering-Plough said in a press statement. The company noted that the products are "the leading female sex hormone products" in France and Belgium, where they are marketed under tradenames Utrogestan and Oestragel by the French firm Laboratoire Basins Iscovesco, while had filed the INDs at FDA. The firms are colicensees. They predicted that the first product developed under the agreement could be approved by FDA in early 1989. The firms estimate that the estrogen replacement market has grown 25% annually and could reach "$ 750 mil. in factor sales within five years." LaSalle Laboratories is based in Washington, D.C. It is a private start-up firm established in late 1987 as a "speciality gynecological company." The company is headed by Washington lawyer Michael Morrell. LaSalle is in the process of hiring managers. Under the agreement, LaSalle will focus its marketing efforts on gynecologists. Schering-Plough will concentrate on primary care physicians and hospitals.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel